Rita Coutinho

i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

John G. Gribben

Barts Health NHS Trust

Andrew Clear

Queen Mary University of London

María Gomes da Silva

Instituto Português de Oncologia Francisco Gentil

Janet Matthews

Flinders University

Maria Calaminici

Queen Mary University of London

José Cabeçadas

IPO Porto

Abigail Lee

George Washington University

Rute Alvarez

Instituto Português de Oncologia Francisco Gentil

Andrew Owen

University of Liverpool

Andrew Wilson

St Vincent's Hospital

Cooperative Institutions

Queen Mary University of London

Centro Hospitalar do Porto

Hospitais da Universidade de Coimbra

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

University of Coimbra

Hospital de Santo António

Instituto Português de Oncologia Francisco Gentil

Universidade do Porto

Universitat de Barcelona

Hospital Clínic de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Rita Coutinho Andrew Clear Andrew Owen A. S. Wilson Janet Matthews

PDF file 265K, Supplementary Figure 1: Immunohistochemistry results for each antibody (A) BCL2; (B) CD10; (C) MUM1; (D) LMO2; (E) GCET1; (F) BCL6; (G) FOXP1. Original magnification: x20

Concordance

10.1158/1078-0432.22446938.v1

Cite

Citations (0)

Supplementary Table S2 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Rita Coutinho Andrew Clear Andrew Owen A. S. Wilson Janet Matthews

PDF file 51K, Supplementary Table S2 Distribution of R-CHOP treated patients diagnosed in the two institutions according to the nine IHC classifiers

Concordance

Table (database)

10.1158/1078-0432.22446932.v1

Cite

Citations (0)

Exploring biomarkers from the tumour and the microenvironment in Diffuse Large B-cell Lymphoma.

Rita Coutinho

Source

Cite

Citations (0)

The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies

Blood (2013)

Konstantinos Liapis Andrew Clear Andrew Owen Rita Coutinho Paul Greaves

Pathophysiology

Infiltration (HVAC)

10.1182/blood-2013-03-488171

Cite

Citations (54)

Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies

Rita Coutinho Andrew Clear Andrew Owen Andrew Wilson Janet Matthews

PDF file 54K, Supplementary Table S1 Primary antibodies and conditions of use

Concordance

Table (database)

10.1158/1078-0432.22446935.v1

Cite

Citations (0)

HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era

AIDS (2013)

Rita Coutinho Alessia Dalla Pria Shreyans Gandhi Katharine Bailey Paul Fields

To compare the outcome of patients diagnosed with HIV infection and diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP in the cART era with that of a HIV-negative control group.From 2003 to 2011, 305 patients (97 HIV-positive) were diagnosed with DLBCL and treated with R-CHOP. Clinical features were compared using chi-square or Fisher's exact test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Multivariate analysis was performed using the Cox regression proportional hazards model.HIV-positive patients had more B symptoms and extranodal sites of disease at diagnosis, but the proportion of patients with high-intermediate/high-risk disease according to the international prognostic index (IPI) was similar between groups. Response rate was 73%, both for patients with and without HIV infection. After a median follow-up of 48 months, 30 patients relapsed after achieving a complete remission, including four HIV-positive patients. Ninety-six patients have died (19 HIV-positive), 73 of them due to DLBCL. Three patients (one HIV-positive) died due to treatment toxicity. Patients with HIV infection had a significantly longer disease-free survival (DFS) (5-year: 94 vs. 77%; P = 0.03) and overall survival (OS) (78 and 64% for HIV-positive and HIV-negative patients, respectively; P = 0.03). These results were confirmed on multivariate analysis when controlled for other potential prognostic confounders.HIV-positive patients diagnosed with DLBCL in the cART era have an excellent outcome when treated with standard immunochemotherapy. Therefore, the choice of chemotherapy in patients with lymphoma should not be influenced by HIV status.

International Prognostic Index

Cart

B symptoms

Log-rank test

10.1097/qad.0000000000000133

Cite

Citations (67)

[Critical analysis of arrhythmias induced by an ergometric test].

PubMed (1984)

de Oliveira Júnior W Toscano Ac Rita Coutinho Monteiro Mde F

Source

Cite

Citations (0)

Clinical Characteristics, Treatment and Evolution of Splenic and Nodal Marginal Zone Lymphomas—Retrospective and Multicentric Analysis of Portuguese Centers

Clinical Lymphoma Myeloma & Leukemia (2021)

Catarina Dantas Rodrigues Rita Pinho Peixeiro Diana Viegas Pedro Chorão Maria Eduarda Couto

Cumulative incidence

10.1016/j.clml.2021.06.013

Cite

Citations (8)

Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis

Current Biomarker Findings (2013)

John G. Gribben Rita Coutinho

Abstract: Introduction of immunochemotherapy as frontline treatment for diffuse large B-cell lymphoma (DLBCL) has significantly increased survival. However, patients refractory to rituximab-containing regimens have a very poor survival. These differences in clinical behavior might lie behind the biological heterogeneity well recognized in this disease. Advanced molecular research has helped us to define DLBCL subgroups which harbor distinct oncogenic events and response to immunochemotherapy. The field of biomarker discovery in DLBCL has become more complex over the last decade and a broad up-to-date review on this topic is lacking. The aim for this review was to offer the hematology community a comprehensive overview of clinical and biological markers which have a diagnostic and prognostic potential and that might be amenable to therapeutic targeting. Some well known markers are reassessed in light of recent findings. Keywords: DLBCL, immunochemotherapy, rituximab, biomarkers

10.2147/cbf.s29208

Cite

Citations (3)

Life expectancy of young adults with follicular lymphoma

Annals of Oncology (2015)

Annarita Conconi Chiara Lobetti‐Bodoni Silvia Montoto Armando López‐Guillermo Rita Coutinho

Follicular lymphoma

10.1093/annonc/mdv376

Cite

Citations (32)